• info@platform-residras.com

International Registry of Dravet Syndrome and other Syndromes correlated with genes on SCN1A and PCDH19

Sudden Unexplained Death in Epilepsy (SUDEP): Risks and Prevention Sudden Unexplained Death in Epilepsy (SUDEP) refers to the unexplained death of a seemingly healthy person with epilepsy where no cause of death can be found. What do doctors need to know about this mysterious and devastating phenomenon? Dr. Elizabeth ...
DESIREepilepsyproject.eu Participants at the final annual meeting of the DESIRE project, Florence Italy 12 -13 Sept 2018
Pubblication around Dravet Syndrome and Drug Resistant Epilepsy shared DESIREepilepsyproject.eu's post.
Malattie rare. Ne soffrono 30 milioni di europei. Le strategie di Ema per lo sviluppo... L’Agenzia europea del farmaco fa il punto sullo sviluppo di farmaci per le malattie rare. Ad oggi, nella UE sono commercializzati oltre 140 farmaci orfani che offrono nuove opzioni di trattamento per i pazienti.
Pubblication around Dravet Syndrome and Drug ...
Zogenix Announces New Data on Psychological and Socioeconomic Impact of Dravet Syndrome and Other Epileptic... The Investor Relations website contains information about Zogenix, Inc's business for stockholders, potential investors, and financial analysts.
Pubblication around Dravet Syndrome and Drug Resistant Epilepsy shared a link.
GW Pharmaceuticals presents latest cannabidiol oral solution (CBD) data at the 13th European Congress of... Vienna, Austria, 28 August 2018: GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the development and commercialization of cannabinoid prescription medicines, presents a variety of data on cannabidiol oral solution (CBD) at the ...
Selective NaV1.1 activation rescues Dravet syndrome mice from seizures and premature death Spider venom is a rich source of peptides, many targeting ion channels. We assessed a venom peptide, Hm1a, as a potential targeted therapy for Dravet syndrome, the genetic epilepsy linked to a mutation in the gene encoding the sodium channel ...
Epidiolex in Italia: farmaco CBD per epilessia - Farmagalenica Disponibilità di Epidiolex in Italia, farmaco non stupefacente con CBD cannabidiolo in farmacia, da cannabis per sindrome Lennox-Gastautsindrome o Dravet.
Pubblication around Dravet Syndrome and Drug Resistant Epilepsy shared a link.
A prospective open‐label trial of a CBD/THC cannabis oil in dravet syndrome - McCoy -... Annals of Clinical and Translational Neurology Volume 0, Issue 0 Research Article Open Access A prospective open‐label trial of a CBD/THC cannabis oil in dravet syndrome Bláthnaid McCoy Corresponding Author E-mail address:blathnaid.mccoy@sickkids.ca Division of Neurology, the Hospital for Sick Ch...
...
epiXchange 2018 The weekend is just around the corner - time 4 some fresh stuff: Pls find here the project overviews by the 7 epiXchange organising coordinators from DESIREepilepsyproject.eu, Epicare ERN, @EpimiRNA, #EpiPGX, Tuberous Sclerosis - Epistop project, EPITARGET & Epixchange: https://youtu.be/V1nf2lSUti8
...
Ovid – ElektraStudy consider the ELEKTRA trial. ELEKTRA is a clinical trial for children with epileptic seizures associated with Dravet syndrome or Lennox-Gastaut syndrome. It will test TAK-935 to find out if it can help lower the number of seizures experienced in these ...
Zogenix's seizure drug clears late-stage trial, shares soar Zogenix Inc said on Thursday its drug to treat a rare form of childhood epilepsy reduced convulsive seizures in a second late-stage trial, sending the drug developer's shares up as much as 26 percent.
Pubblication around Dravet Syndrome and Drug ...
Long‐term safety and treatment effects of cannabidiol in children and adults with treatment‐resistant epilepsies: Expanded... Epilepsia Volume 0, Issue 0 FULL‐LENGTH ORIGINAL RESEARCH Open Access Long‐term safety and treatment effects of cannabidiol in children and adults with treatment‐resistant epilepsies: Expanded access program results Jerzy P. Szaflarski Corresponding Author E-mail address:jszaflarski@uabmc.edu ...
Pubblication around Dravet Syndrome ...
Zogenix: successo candidato ZX008 contro forma rara di epilessia In uno studio di fase avanzata, il candidato ZX008 di Zogenix per il trattamento con sindrome di Dravet, una rara forma di epilessia
Pubblication around Dravet Syndrome and Drug Resistant Epilepsy shared a link.
GW Pharmaceuticals plc and its U.S. Subsidiary Greenwich Biosciences Announce FDA Approval of EPIDIOLEX® (cannabidiol)... Approval for seizures associated with Lennox-Gastaut Syndrome or Dravet Syndrome, two rare, severe childhood-onset epilepsies
Pubblication around Dravet Syndrome and Drug Resistant Epilepsy shared a link.
Prossima l'approvazione FDA del primo farmaco derivato dalla cannabis La prossima settimana la FDA potrebbe approvare il primo farmaco derivato dalla cannabis. Si tratta di un prodotto della britannica GW Pharmaceuticals che
Pubblication around Dravet Syndrome and Drug Resistant Epilepsy shared a link.
ILAE - International League Against Epilepsy Read the June 2018 ILAE Newsletter: New Classification Translations | Young Epilepsy Section | Spotlight on Georgia | VIREPA Applications open | Journal News | Congress deadlines: http://p0.vresp.com/vhtuGW.
If you want to sign up to receive the monthly news via ...
Quartz Columbia University researchers made a major breakthrough in teaching kids with cerebral palsy how to walk better.
Pubblication around Dravet Syndrome and Drug Resistant Epilepsy shared Quartz's video.

Load More